Last edition
News about "IGALMI FDA acceptance"
BioXcel Therapeutics Announces FDA Acceptance of Supplemental NDA for IGALMI
BioXcel Therapeutics receives FDA acceptance for supplemental NDA of IGALMI, targeting acute agitation in bipolar disorder and schizophrenia for potential at-home treatment use.
IGALMI FDA Acceptance | 02/04/2026 | By News Bureau | 102
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members